Biotech RadarJobs updated

COMPANY

Reven Pharmaceuticals

reven.com ↗ · Mountain

Past trials only

Keywords: COVID-19 adult respiratory distress syndrome sepsis Critical Limb Ischemia Acute Respiratory Distress Syndrome SARS-CoV-2 Hypoxemia Peripheral Arterial Disease Rejuveinix (RJX) Active Comparator

Profile checked Oct 10, 2026

3Trials (company is sponsor)

Timeline

  1. Trial start Phase 1/Phase 2: Tolerability and Efficacy of RJX in Patients With COVID-19 source ↗
  2. Trial start Phase 1/Phase 2: Revascularization of Stenosed Vessels Using Optimized Treatment of Rejuveinix for Reversing Endothelial Dysfunction source ↗
  3. Trial start Phase 1: A Safety and Tolerability Study of RJX Drug Product in Healthy Participants source ↗

Clinical trials (lead sponsor) 3

RecordTitlePhaseStatusStartPrimary completion
NCT04708340Tolerability and Efficacy of RJX in Patients With COVID-19Phase 1/Phase 2Unknown status (ClinicalTrials.gov)Mar 25, 20212022-10 (estimated)
NCT03680105A Safety and Tolerability Study of RJX Drug Product in Healthy ParticipantsPhase 1CompletedAug 24, 2018Jan 15, 2019 (actual)
NCT03041259Revascularization of Stenosed Vessels Using Optimized Treatment of Rejuveinix for Reversing Endothelial DysfunctionPhase 1/Phase 2Unknown status (ClinicalTrials.gov)2020-012022-01 (estimated)
Feedback